ESSA Securityholders Approve Acquisition by XenoTherapeutics Non-Profit Biotech

ESSA Pharma shareholders approved the acquisition of the company by XenoTherapeutics, a non-profit biotech firm, through a statutory plan of arrangement at a special meeting. The acquisition was approved by 99.83% of the votes cast by shareholders present or represented by proxy. ESSA Pharma's common shares will be acquired by XenoTherapeutics.

In a significant move for the biotechnology sector, ESSA Pharma Inc. shareholders have overwhelmingly approved the acquisition of the company by XenoTherapeutics Inc. The approval came at a special meeting held on October 6, 2025, where 99.83% of the votes cast by shareholders present or represented by proxy voted in favor of the acquisition ESSA Securityholders Approve Acquisition by XenoTherapeutics^[1].

The acquisition, facilitated through a statutory plan of arrangement, will see XenoTherapeutics, a non-profit biotechnology research foundation, take over all of ESSA's common shares. This move marks a strategic shift for both companies, with XenoTherapeutics aiming to leverage ESSA's expertise in prostate cancer treatments to advance its xenotransplantation research.

The special resolution approving the arrangement was supported by an overwhelming majority of 99.85% of the votes cast by shareholders, holders of options, and pre-funded purchase warrants. Additionally, shareholders approved the compensation for executive officers and the appointment of a liquidator, should the arrangement be terminated ESSA Securityholders Approve Acquisition by XenoTherapeutics^[1].

The acquisition is subject to the approval of the Supreme Court of British Columbia and other customary closing conditions. The court hearing for the final order is scheduled for October 7, 2025, with the completion of the arrangement expected to occur on or about October 9, 2025 ESSA Securityholders Approve Acquisition by XenoTherapeutics^[1].

About ESSA Pharma Inc.
ESSA Pharma Inc. is a pharmaceutical company previously focused on developing novel therapies for prostate cancer. For more information, please visit [www.essapharma.com](http://www.essapharma.com).

About XenoTherapeutics Inc.
XenoTherapeutics Inc. is a Massachusetts-based 501(c)(3) research foundation focused on advancing xenotransplantation through scientific research, clinical development, and public education. For more information, please visit [www.xenotx.org](http://www.xenotx.org).

Forward-Looking Statements
The announcement includes forward-looking statements, which are subject to various risks and uncertainties, including the completion of the transaction and the potential benefits thereof. These risks are more fully discussed in the definitive proxy statement and management information circular filed with the U.S. Securities and Exchange Commission on August 11, 2025, and supplemental proxy statement dated September 24, 2025 ESSA Securityholders Approve Acquisition by XenoTherapeutics^[1].

References
ESSA Securityholders Approve Acquisition by XenoTherapeutics^[1] https://www.prnewswire.com/news-releases/essa-securityholders-approve-acquisition-by-xenotherapeutics-302576261.html